TNGX
Price:
$3.04
Market Cap:
$326.55M
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in...[Read more]
Industry
Biotechnology
IPO Date
2020-09-03
Stock Exchange
NASDAQ
Ticker
TNGX
According to Tango Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 311.03M. This represents a change of -64.65% compared to the average of 879.91M of the last 4 quarters.
The mean historical Enterprise Value of Tango Therapeutics, Inc. over the last ten years is 497.32M. The current 311.03M Enterprise Value has changed 6.15% with respect to the historical average. Over the past ten years (40 quarters), TNGX's Enterprise Value was at its highest in in the September 2023 quarter at 1.07B. The Enterprise Value was at its lowest in in the June 2020 quarter at 114.51M.
Average
497.32M
Median
538.22M
Minimum
76.92M
Maximum
908.80M
Discovering the peaks and valleys of Tango Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 348.27%
Maximum Annual Enterprise Value = 908.80M
Minimum Annual Increase = 0%
Minimum Annual Enterprise Value = 76.92M
Year | Enterprise Value | Change |
---|---|---|
2023 | 908.80M | 47.09% |
2022 | 617.86M | 14.80% |
2021 | 538.22M | 56.09% |
2020 | 344.81M | 348.27% |
The current Enterprise Value of Tango Therapeutics, Inc. (TNGX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
688.29M
5-year avg
497.32M
10-year avg
497.32M
Tango Therapeutics, Inc.’s Enterprise Value is greater than Third Harmonic Bio, Inc. (172.31M), less than Cullinan Oncology, Inc. (614.81M), less than Edgewise Therapeutics, Inc. (2.76B), greater than Rallybio Corporation (10.47M), less than Monte Rosa Therapeutics, Inc. (351.25M), greater than Connect Biopharma Holdings Limited (-54815984.00), less than Tyra Biosciences, Inc. (647.39M), greater than RAPT Therapeutics, Inc. (27.70M), greater than Xilio Therapeutics, Inc. (-2292216.00), less than Mineralys Therapeutics, Inc. (539.76M), greater than Foghorn Therapeutics Inc. (260.47M), greater than Shattuck Labs, Inc. (12.78M), less than Kymera Therapeutics, Inc. (2.62B), less than Nurix Therapeutics, Inc. (1.31B), greater than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (7.98B), greater than Black Diamond Therapeutics, Inc. (123.50M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (33.76M), less than Relay Therapeutics, Inc. (605.49M), less than Stoke Therapeutics, Inc. (451.87M), less than Pliant Therapeutics, Inc. (801.51M), less than Arvinas, Inc. (1.20B),
Company | Enterprise Value | Market cap |
---|---|---|
172.31M | $465.00M | |
614.81M | $714.45M | |
2.76B | $2.80B | |
10.47M | $35.56M | |
351.25M | $433.13M | |
-54815984.00 | $55.03M | |
647.39M | $744.96M | |
27.70M | $60.48M | |
-2292216.00 | $50.55M | |
539.76M | $637.04M | |
260.47M | $279.08M | |
12.78M | $52.99M | |
2.62B | $2.64B | |
1.31B | $1.39B | |
79.12M | $58.11M | |
7.98B | $8.09B | |
123.50M | $123.92M | |
-8620212.00 | $3.57M | |
33.76M | $40.24M | |
605.49M | $708.03M | |
451.87M | $599.59M | |
801.51M | $820.92M | |
1.20B | $1.29B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tango Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tango Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Tango Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Tango Therapeutics, Inc. (TNGX)?
What is the 3-year average Enterprise Value for Tango Therapeutics, Inc. (TNGX)?
What is the 5-year average Enterprise Value for Tango Therapeutics, Inc. (TNGX)?
How does the current Enterprise Value for Tango Therapeutics, Inc. (TNGX) compare to its historical average?